Cytestrol acetate

Cytestrol acetate is a steroidal antiestrogen and a cytostatic antineoplastic agent (i.e., chemotherapeutic) which was developed for the treatment of breast cancer but was never marketed.[1][2][3][4]

Cytestrol acetate
Clinical data
Other names11α-Hydroxyethinylestradiol 3-(bis(2-chloroethyl)carbamate) 11α,17β-diacetate; 17α-Ethynylestra-1,3,5(10)-triene-3,11α,17β-triol 11α,17β-diacetate 3-(bis(2-chloroethyl)carbamate)
Identifiers
  • (1S,10S,11S,14R,15S,17R)-17-(Acetyloxy)-5-{[bis(2-chloroethyl)carbamoyl]oxy}-14-ethynyl-15-methyltetracyclo[8.7.0.02,7.011,15]heptadeca-2,4,6-trien-14-yl acetate
ChemSpider
Chemical and physical data
FormulaC29H35Cl2NO6
Molar mass564.50 g·mol−1
3D model (JSmol)
  • [H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(C)C[C@@H](OC(C)=O)[C@]1([H])C3=CC=C(OC(=O)N(CCCl)CCCl)C=C3CC[C@@]21[H]
  • InChI=1S/C29H35Cl2NO6/c1-5-29(38-19(3)34)11-10-24-23-8-6-20-16-21(37-27(35)32(14-12-30)15-13-31)7-9-22(20)26(23)25(36-18(2)33)17-28(24,29)4/h1,7,9,16,23-26H,6,8,10-15,17H2,2-4H3/t23-,24-,25+,26+,28-,29-/m0/s1
  • Key:RRJRVDYYFLBGSE-UPRLNUCLSA-N

It is an 11α-hydroxylated derivative of ethinylestradiol in which a bis(2-chloroethyl)amine nitrogen mustard moiety has been attached as an ester at the C3 position and acetate esters have been attached at the C11α and C17β positions.[1][2][3][4] The mechanism of action of cytestrol acetate in breast cancer is two-fold: (1) acting as an antiestrogen similarly to fulvestrant or ICI-164384; and (2) having cytostatic actions via the carbamate–nitrogen mustard moiety analogously to estramustine phosphate.[1][2][3][4] The drug shows potent efficacy against breast cancer superior to that of tamoxifen in in vitro models.[1][2][3]

See also

  • World War II

References

  1. Oborotov AV, Smirnova ZS, Osetrova IP, Polozkova AP, Rzheznikov VM (1999). "Antitumor activity of various medicinal forms of the new estrogenocytostatic drug cytestrol acetate". Pharmaceutical Chemistry Journal. 33 (10): 526–527. doi:10.1007/BF02508372. ISSN 0091-150X. S2CID 5550495.
  2. Smirnova ZS, Rzheznikov VM, Tolkachev VN, Borisova LM, Kiseleva MP, Semeĭkin AV, et al. (2014). "[Antitumor and antiproliferative action of the steroidal cytostatic antiestrogen cytestrol acetate on hormone-dependent tumor models]". Eksperimental'naia i Klinicheskaia Farmakologiia (in Russian). 77 (10): 31–35. PMID 25518525.
  3. Smirnova ZS (2003). "[Experimental Study of Hormonocytostatics for Treatment of Breast Cancer.]" [Russian biotherapeutic journal]. Российский биотерапевтический журнал (in Russian). 2 (2).
  4. Smirnova ZS, Rzheznikov VM, Tolkachev VN, Borisova LM, Kiseleva MP, Semeykin AV, Fedocheva TA, Shirokikh KE, Banin VV, Shimanovsky NL (November 2014). "Противоопухолевое и антипролиферативное действие стероидного антиэстрогена цитэстрола ацетата на моделях гормонозависимых опухолей" [Antitumor and antiproliferative effects of the steroid antiestrogen citestrol acetate in models of hormone-dependent tumors.]. Экспериментальная и клиническая фармакология [Experimental and clinical pharmacology.] (in Russian). 77 (10): 31–35.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.